Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

There’s No Question Canopy Growth Stock Wins in the Long Term

By Chris Lau, InvestorPlace Contributor

Martha Stuart's investment in Canopy Growth stock grabs headlines but does it mean you should follow the trade?

Why Uber Stock Might Just Be an Easy Short-Selling Trade for Bears

By Chris Lau, InvestorPlace Contributor

Uber stock is an easy target for short-sellers. The company may not make a profits for years and the post-IPO performance is a bust.

Cronos Stock Peaked But It Still Holds Promise

By Chris Lau, InvestorPlace Contributor

Cronos shares peaked months ago at $24 and its latest Q1 report failed to attract buyers. But there are still reasons to be optimistic.

Why Aurora Cannabis Stock Could Break Out From Its Trading Range

By Chris Lau, InvestorPlace Contributor

Aurora Cannabis stock is down after Statistics Canada reported flat cannabis demand. Should that matter for ACB stock?

Will Microsoft Stock Soon Have a $1 Trillion Market Cap?

By Chris Lau, InvestorPlace Contributor

The rapid growth of Azure, MSFT's cloud business, can meaningfully boost Microsoft stock. Investors are underestimating the impact of Azure on MSFT stock.

Load More